Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group

Trial Profile

Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms AZABACHE
  • Sponsors PETHEMA Foundation
  • Most Recent Events

    • 25 Oct 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 14 Sep 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 16 Sep 2015 Planned End Date changed from 1 Nov 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top